Astellas CEO Says Engaging With Activist Investor Farallon
This article is for subscribers only.
Astellas Pharma Inc. will continue to engage with Farallon Capital Management, an activist investor that’s built a stake in the Japanese drugmaker, Chief Executive Officer Naoki Okamura said, adding that he’s “pleased that one of our investors sees potential value” in the company.
“Ultimately, all shareholders want to increase corporate value and we share the exactly the same mission,” Okamura told Bloomberg TV in an interview, declining to give details of the discussions with Farallon. “We receive various proposals from shareholders, and if we see something that will indeed contribute to enhancing our corporate value, then of course we are willing to accept it.”